Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04109729 · ClinicalTrials.gov registry record · Phase 1

Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer

A Phase 1 study of Metastatic Castration-Resistant Prostate Cancer, sponsored by University of Utah.

Active
Registry status
Phase 1
Development phase
39
Enrollment target
1
Study location

NCT04109729: Active Phase 1 study of Metastatic Castration-Resistant Prostate Cancer, sponsored by University of Utah.

NCT04109729 is a Phase 1 study of Metastatic Castration-Resistant Prostate Cancer that is active but no longer recruiting, run by University of Utah. The registered enrollment target is 39 participants, below the 197-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04109729, a Phase 1 study of Metastatic Castration-Resistant Prostate Cancer, is active but no longer recruiting, sponsored by University of Utah.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
39 participants
Enrollment target
1
Study location

Study Summary

This is a phase 1, open label, prospective, non-randomized single arm study combining Radium-223 with nivolumab in men with metastatic castration resistant prostate cancer.

Primary Outcome

Frequency of adverse events (AEs) characterized by seriousness, severity (as defined by CTCAE, version 5.0), duration, and relationship to study therapy. An increase in the clinically significant, non-hematologic grade 3 or greater toxicities above that observed in the Checkmate-214 trial will be considered unacceptable.

Conditions Studied

Metastatic Castration-Resistant Prostate Cancer

Interventions

  • DRUG Nivolumab
  • DRUG Radium-223

Study Locations (1)

Utah

  • Huntsman Cancer Institute at University of Utah - Salt Lake City

Trial Details

FieldValue
Enrollment Target 39 participants
Start Date 2020-09-16
Est. Completion 2026-04-30
Phase Phase 1
University of Utah

818 total trials

What the registry record for NCT04109729 still lists

NCT04109729 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 197-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (80% lower).

The record links to 1 condition, with Metastatic Castration-Resistant Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.

NCT04109729 reports a single indexed study location in Utah.

Frequently Asked Questions

What is clinical trial NCT04109729 about?

NCT04109729 is a clinical study titled "Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer". This is a phase 1, open label, prospective, non-randomized single arm study combining Radium-223 with nivolumab in men with metastatic castration resistant prostate cancer.

What is the current status of trial NCT04109729?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2020-09-16. Estimated completion is 2026-04-30.

What conditions does trial NCT04109729 study?

This clinical trial studies the following conditions: Metastatic Castration-Resistant Prostate Cancer.

What interventions are being tested in trial NCT04109729?

The interventions under investigation include: Nivolumab (DRUG), Radium-223 (DRUG).

Who is sponsoring clinical trial NCT04109729?

This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04109729 being conducted?

This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Castration-Resistant Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04109729's enrollment target sits among peer trials

39 51st of 69 higher than 19 of 69 other Metastatic Castration-Resistant Prostate Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Metastatic Castration-Resistant Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03465592 · 39 participants · Phase 1

    Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma

  • NCT03961776 · 39 participants

    Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems

  • NCT04050280 · 39 participants · Phase 2

    CLAG-GO for Patients With Persistent, Relapsed or Refractory AML

  • NCT04190862 · 39 participants · Phase 1

    E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT04109729, the US trial registry maintained by the National Library of Medicine. NCT04109729 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.